Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period

NCT ID: NCT03091907

Last Updated: 2018-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-05

Study Completion Date

2018-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim

The aim of this study is to determine consequences at school age of the diagnosis of NEC in the neonatal period.

Methods

This is a case-control study, with case-group being children born in Denmark with a history of NEC and control-group being age-, gestational age- and year of birth matched children born in Denmark with no history of NEC.

Primary outcome

Abnormal or borderline 'total difficulties score' in the strenghts-and-difficulties-questionnaire as assessed by parents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale

Knowledge of the long-term complications related to necrotizing enterocolitis (NEC) in the neonatal period is essential, when clinicians are counseling parents about the risk for complications following NEC. When deciding upon a follow-up strategy for the infant after discharge, this knowledge is also crucial. If the infant has an increased risk for complications later in life, a closer follow up is important to assure proper handling of complications.

So far, a definite conclusion regarding long-term complications of NEC has not been made. A systematic review including ten studies, have shown a significantly increased risk for neurodevelopmental impairment in NEC children. However, the median follow-up time did not exceed two years and may not reflect the true long-term complications. The ORACLE Children Study investigated neurodevelopmental impairments in children with a history of NEC at 7,5 year follow-up and found no increased risk.

No review has been published regarding growth impairments and so far, available studies have a less than three year follow-up period and are reporting conflicting results.

Gastrointestinal morbidities are even less investigated and reports no association with NEC within three years follow-up. However, the ORACLE Children Study found increased risk of bowel problems at 7,5 years follow-up in children with a history of NEC.

The Oracle Children Study and Roze et al reported behavioural problems in up to 30% of children with a history of NEC at school age, but no statistic significance was found when compared to a control-group.

Further studies investigating the outcome of NEC-children at school age are needed.

Objectives

The investigators plan to conduct a retrospective parental-questionnare study, to determine the long-term complications related to the diagnosis of NEC at school age (5-15 years of age).

Methods

This is a case-control study. Case-group will include all surviving children born in Denmark between 1st of January 2002 and 31st of December 2011 with an international classification of diseases (ICD-10) diagnosis of NEC at discharge. Matching each child with a history of NEC to two children with no history of NEC by gestational age, year of birth and birthweight will form the control group. Matching criteria's have been chosen to balance prematurity and age at follow-up between case and control-group. Parental follow-up questionnaires regarding complications will be sent to all parents of cases and controls.

Clinical data on the children, regarding birth and neonatal history, will be obtained and used in a mixed regression model to adjust for possible confounders.

Primary outcome

Abnormal or borderline 'total difficulties score' in the strenghts-and-difficulties-questionnaire as assessed by parents.

Secondary outcomes

1. Severe cerebral palsy (GMFCS III-IV)
2. Head circumference as measured by parents
3. Height as measured by parents
4. Abdominal symptoms resulting in significant absence from school as reported by parents
5. Diarrhoea within the last six months
6. Constipation within the last six months

Power calculation

The sample size for the case group was estimated to include 200 children with NEC (after a no-response drop out of 20%) and in the control group 300 children without NEC, with a 1:2 match ratio and the assumption that the response rate will be lower in the control group., i.e. 250 parents of children with NEC and 500 parents of control children will be contacted.

SDQ total score Assuming 30% prevalence of abnormal or borderline scores for 'total difficulties' in the strength-and-difficulties-questionnaire in NEC-survivors, compared to an assumed 20% in controls (19), this study will detect the difference with a power of 72% at a 5% significance level.

Severe cerebral palsy (GMFCS score III-V) Assuming a 20% prevalence (9) of severe cerebral palsy in NEC-survivors compared to an assumed 10% in controls (22) this study will detect the difference with a power of 87% at a 5% significance level.

Head circumference The power calculation on our cohort shows that we, at a 5% significance level, can detect the difference in mean head circumference at 0.3 standard-deviations or more, with a power of 90%.

Analysis plan

Primary outcome: a p-value \< 0.05 will be considered significant. To determine a difference in SDQ-scores between case- and control group, Chi-squared test or Fischer's Exact test will be used as appropriate.

Secondary outcome: a p-value \< 0.01 will be considered significant. Differences in 'height', 'head circumference' and 'absence from school due to abdominal symptoms' will be investigated by t-test or Mann-Whitney's test as appropriate. 'Severe cerebral palsy', 'diarrhoea' and 'constipation' will be analyzed by Chi-squared test or Fischer“s Exact test as appropriate.

At first, an unadjusted analysis will be performed to investigate differences in primary and secondary outcome. Secondly, a mixed regression model will be used to adjust for possible confounders

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NEC - Necrotizing Enterocolitis Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Children with a history of necrotizing enterocolitis

No interventions assigned to this group

control

Children with no history of necrotizing enterocolitis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Born from 1st of January 2002 to 31st of December 2011
* ICD-10 diagnosis of NEC (DP77.9)
* Survival at follow-up
* Response to questionnaire


* Born from 1st of January 2002 to 31st of December 2011
* Matched by year of birth, birthweight and gestational age to children in case-group
* Survival at follow-up
* Response to questionnaire

Exclusion Criteria

* Death before follow-up
* Non-responders to questionnaire
Minimum Eligible Age

5 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gorm Greisen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gorm Greisen

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gorm Greisen, Professor, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neonatalklinikken, Rigshospitalet

Copenhagen, Capital Region, Denmark

Site Status

Department of Neonatology, Rigshospitalet

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-58-0004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Metoclopramide Pilot Trial
NCT02098915 TERMINATED PHASE3
The Motility Mother-Child Cohort
NCT05491161 ACTIVE_NOT_RECRUITING